Affinity Capital Advisors, LLC Fate Therapeutics Inc Transaction History

Affinity Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 11, 2022	SELL	$17.78 - $42.39 $131,749 - $314,109	-7,410 Closed	0 $0
Q1 2022 Apr 19, 2022	BUY	$29.67 - $60.28 $1,513 - $3,074	51 Added 0.69%	7,410 $287,000
Q4 2021 Jan 31, 2022	BUY	$47.84 - $64.34 $956 - $1,286	20 Added 0.27%	7,359 $431,000
Q4 2020 Jan 27, 2021	SELL	$38.09 - $100.95 $27,805 - $73,693	-730 Reduced 9.05%	7,339 $667,000
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $28,433 - $37,867	-935 Reduced 10.38%	8,069 $323,000
Q1 2020 Apr 23, 2020	SELL	$17.28 - $31.88 $57,974 - $106,957	-3,355 Reduced 27.15%	9,004 $282,000
Q4 2019 Apr 23, 2020	BUY	$13.39 - $20.73 $165,487 - $256,202	12,359 New	12,359 $242,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Affinity Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Capital Advisors, LLC with notifications on news.